ERBB2 and cancer: Ziteng et al. constructed a pan-cancer predictive index of anti-HER2 therapies across 33 tumor types, including breast cancer, which highlighted the importance of incorporating transcriptional patterns into the assessment of HER2 status for better patient selection 9.